Robin T. Zon
Experienced in Gitelman Syndrome

Dr. Robin T. Zon

Oncology | Hematology Oncology
5340 Holy Cross Pkwy, 
Mishawaka, IN 
Accepting New Patients
Experienced in Gitelman Syndrome
5340 Holy Cross Pkwy, 
Mishawaka, IN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Robin Zon is an Oncologist and a Hematologist Oncology provider in Mishawaka, Indiana. Dr. Zon is rated as an Experienced provider by MediFind in the treatment of Gitelman Syndrome. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Severe Congenital Neutropenia, and Lung Cancer. Dr. Zon is currently accepting new patients.

Her clinical research consists of co-authoring 43 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology Oncology
Licenses
Internal Medicine in IN
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

5340 Holy Cross Pkwy, Mishawaka, IN 46545
Other Locations
615 N Michigan St, South Bend, IN 46601

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 08, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Chemotherapy, Erlotinib hydrochloride, Fluorouracil, Gemcitabine hydrochloride
Study Phase: Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women With Breast Cancer
Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women With Breast Cancer
Enrollment Status: Completed
Publish Date: September 05, 2025
Intervention Type: Procedure
Study Phase: Phase 3
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
Enrollment Status: Terminated
Publish Date: January 24, 2025
Intervention Type: Biological, Drug
Study Drugs: HSPPC-96, Bevacizumab
Study Phase: Phase 2
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 10, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Anastrozole
Study Phase: Phase 3
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
Enrollment Status: Active_not_recruiting
Publish Date: February 02, 2024
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 2/Phase 3
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
View 10 Less Clinical Trials

42 Total Publications

A New Approach to Cancer Second Opinions: Overcoming the Challenges of Conventional Oncology Practice by Providing Education to Patients and Physicians.
A New Approach to Cancer Second Opinions: Overcoming the Challenges of Conventional Oncology Practice by Providing Education to Patients and Physicians.
Journal: Journal of cancer education : the official journal of the American Association for Cancer Education
Published: March 08, 2025
Similar Doctors
Advanced in Gitelman Syndrome
Dr. Ayoola S. Awofadeju
Emergency Medicine | Hematology Oncology
Advanced in Gitelman Syndrome
Dr. Ayoola S. Awofadeju
Emergency Medicine | Hematology Oncology
85 E US Highway 6, 
Valparaiso, IN 
 (46.7 miles away)
219-983-8300
Languages Spoken:
English, Russian, Serbo Croatian, Yoruba
See accepted insurances
Accepting New Patients

Ayoola Awofadeju is an Emergency Medicine specialist and a Hematologist Oncology provider in Valparaiso, Indiana. Dr. Awofadeju is rated as an Advanced provider by MediFind in the treatment of Gitelman Syndrome. His top areas of expertise are Magnesium Deficiency, Morning Sickness, Gitelman Syndrome, and Chronic Inflammatory Response Syndrome (CIRS). Dr. Awofadeju is currently accepting new patients.

Experienced in Gitelman Syndrome
Dr. Rashid Z. Khan
Oncology | Hematology | Hematology Oncology
Experienced in Gitelman Syndrome
Dr. Rashid Z. Khan
Oncology | Hematology | Hematology Oncology

Michiana Hematology-Oncology P C

5340 Holy Cross Pkwy, 
Mishawaka, IN 
 (0.1 miles away)
574-237-1328
Languages Spoken:
English, Hindi, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Rashid Khan is an Oncologist and a Hematologist in Mishawaka, Indiana. Dr. Khan is rated as a Distinguished provider by MediFind in the treatment of Gitelman Syndrome. His top areas of expertise are Multiple Myeloma, Lung Cancer, Childhood Iron Deficiency Anemia, Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Khan is currently accepting new patients.

Experienced in Gitelman Syndrome
Dr. Rafat H. Ansari
Oncology | Hematology Oncology
Experienced in Gitelman Syndrome
Dr. Rafat H. Ansari
Oncology | Hematology Oncology
5340 Holy Cross Pkwy, 
Mishawaka, IN 
 (0.1 miles away)
574-234-5123
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Rafat Ansari is an Oncologist and a Hematologist Oncology provider in Mishawaka, Indiana. Dr. Ansari is rated as a Distinguished provider by MediFind in the treatment of Gitelman Syndrome. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Familial Colorectal Cancer, and Paget Disease of the Breast. Dr. Ansari is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zon's expertise for a condition
ConditionClose
    View All 49 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile